Human medicines European public assessment report (EPAR): Mylotarg, gemtuzumab ozogamicin, Date of authorisation: 19/04/2018, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Mylotarg, gemtuzumab ozogamicin, Date of authorisation: 19/04/2018, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Besponsa, inotuzumab ozogamicin, Date of authorisation: 28/06/2017, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Besponsa, inotuzumab ozogamicin, Date of authorisation: 28/06/2017, Revision: 12, Status: Authorised

EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - Chapter 2: Format for the electronic submission of veterinary medicinal product information

EU Implementation Guide (IG) on veterinary medicines product data in the Union Product Database - Chapter 2: Format for the electronic submission of veterinary medicinal product information

LinkedIn Live: Smarter trials, stronger Europe. New targets for clinical research., European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 24 September 2025, 14:00 (CEST) to 24 September 2025, 15:00 (CEST)

LinkedIn Live: Smarter trials, stronger Europe. New targets for clinical research., European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 24 September 2025, 14:00 (CEST) to 24 September 2025, 15:00 (CEST)

Human medicines European public assessment report (EPAR): Baqsimi, glucagon, Date of authorisation: 16/12/2019, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Baqsimi, glucagon, Date of authorisation: 16/12/2019, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Emselex, darifenacin hydrobromide, Date of authorisation: 22/10/2004, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Emselex, darifenacin hydrobromide, Date of authorisation: 22/10/2004, Revision: 28, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.